Debra King
Known title: See RemarksCIK: 0002055817
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ODFL: No New News in the Past Week. The past week’s headlines focus on other transportation names such as Wabtec, Knight‑Swift, CSX, and Southwest Airlines, with no specific updates for Old Dominion Freight Line. The stock remains near its 9‑touch support at $217.58 and an RSI of 60.1, indicating moderate upward momentum. Its valuation sits at a trailing P/E of 35.6 and a dividend yield of 0.40%, with analysts averaging a target of $221.14 within a 52‑week range of $126.01 to $252.03.
Transaction History
| SYK | ▼ Sell | Open Market | 826 | $278K | 8/18/2026 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 533 | $174K | 8/1/2026 | View on chart |
| SYK | ▲ Buy | Grant | 1,016 | $0 | 5/6/2026 | View on chart |
| SYK | ▲ Buy | Grant | 6,553 | $0 | 8/5/2025 | View on chart |
| ODFL | ▲ Buy | Grant | 1,029 | $0 | 5/21/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.